Overview
A Six-Month, Open-Label, Crossover Study Of the Maintenance Of Serum Testosterone And PSA Suppression After Switching Between Lupron 22.5 Mg And Eligard 22.5 Mg Or Zoladex 10.8 Mg And Eligard 22.5 Mg In Patients With Advanced Prostate Cancer
Status:
Completed
Completed
Trial end date:
2005-06-01
2005-06-01
Target enrollment:
0
0
Participant gender:
Male
Male
Summary
Comparing the effect of switching from Lupron and Zoladex to Eligard. PSA and Testosterone levels are measured at set intervals to determine if Eligard is equal or better then Lupron or Zoladex in advanced Prostate Cancer patients.Phase:
Phase 4Accepts Healthy Volunteers?
NoDetails
Lead Sponsor:
San Bernardino Urological Associates Medical Group IncTreatments:
Goserelin
Leuprolide
Methyltestosterone
Testosterone
Testosterone 17 beta-cypionate
Testosterone enanthate
Testosterone undecanoate
Criteria
Inclusion Criteria: Patient with Advanced Ca, on stable dose of Lupron or Zoladex-
Exclusion Criteria:
- Previous exposure to Eligard.